Herpes zoster burden in patients with asthma: real-world incidence, healthcare resource utilisation and cost

被引:0
作者
Singer, David [1 ]
Thompson-Leduc, Philippe [2 ]
Ma, Siyu [3 ]
Gupta, Deepshekhar [4 ]
Cheng, Wendy Y. [5 ]
Muthukumar, Aruna [4 ]
Devine, Francesca [6 ]
Sundar, Manasvi [7 ]
Bogart, Michael [8 ,9 ]
Hagopian, Ella [5 ]
Poston, Sara [1 ]
Duh, Mei Sheng [5 ]
Oppenheimer, John J. [10 ]
机构
[1] GSK, Philadelphia, PA 19104 USA
[2] Anal Grp Inc, Montreal, PQ, Canada
[3] GSK, Tufts Med Ctr, Boston, MA USA
[4] Anal Grp Inc, Menlo Pk, CA USA
[5] Anal Grp Inc, Boston, MA USA
[6] Anal Grp Inc, New York, NY USA
[7] Anal Grp Inc, Los Angeles, CA USA
[8] GSK, Res Triangle Pk, NC USA
[9] Gilead Sci, Foster City, CA USA
[10] Rutgers New Jersey Med Sch, Newark, NJ USA
关键词
Asthma; Asthma Epidemiology; Health Economist; Viral infection; SUBUNIT VACCINE; ADULTS; RISK; EFFICACY; SCORE; US;
D O I
10.1136/bmjresp-2023-002130
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
Background Herpes zoster (HZ) is a painful condition caused by reactivation of the varicella-zoster virus. The objectives of this study were to compare HZ incidence in adults with asthma versus adults without asthma and to compare healthcare resource use as well as direct costs in adults with HZ and asthma versus adults with asthma alone in the USA.Methods This retrospective longitudinal cohort study included adults aged >= 18 years across the USA. Patients were identified from Optum's deidentified Clinformatics Data Mart Database, an administrative claims database, between 1 October 2015 and 28 February 2020, including commercially insured and Medicare Advantage with part D beneficiaries. Cohorts of patients with and without asthma, and separate cohorts of patients with asthma and HZ and with asthma but not HZ, were identified using International Classification of Diseases 10th Revision, Clinical Modification codes. HZ incidence, healthcare resource use and costs were compared, adjusting for baseline characteristics, between the relevant cohorts using generalised linear models.Results HZ incidence was higher in patients with asthma (11.59 per 1000 person-years) than patients without asthma (7.16 per 1000 person-years). The adjusted incidence rate ratio (aIRR) for HZ in patients with asthma, compared with patients without asthma, was 1.34 (95% CI 1.32 to 1.37). Over 12 months of follow-up, patients with asthma and HZ had more inpatient stays (aIRR 1.11; 95% CI 1.02 to 1.21), emergency department visits (aIRR 1.26; 95% CI 1.18 to 1.34) and outpatient visits (aIRR 1.19; 95% CI 1.16 to 1.22), and direct healthcare costs that were US dollars ($) 3058 (95% CI $1671 to $4492) higher than patients with asthma without HZ.Conclusion Patients with asthma had a higher incidence of HZ than those without asthma, and among patients with asthma HZ added to their healthcare resource use and costs.
引用
收藏
页数:12
相关论文
共 50 条
  • [41] Prospective Real-World Analysis of Asthma Patients With Preserved and Reduced Physical Activity
    Iwamoto, Hiroshi
    Hirano, Tsunahiko
    Amano, Yoshihiro
    Murakawa, Keita
    Fukatsu-Chikumoto, Ayumi
    Yamaji, Yoshikazu
    Yamane, Mayuka
    Anabuki, Kazuki
    Otani, Toshihito
    Higaki, Naoko
    Miyamoto, Shintaro
    Isobe, Takeshi
    Yokoyama, Akihito
    Matsunaga, Kazuto
    Hattori, Noboru
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE, 2023, 11 (09) : 2792 - +
  • [42] Reduction in asthma exacerbation rate after mepolizumab treatment initiation in patients with severe asthma: A real-world database study in Japan
    Nagase, Hiroyuki
    Tamaoki, Jun
    Suzuki, Takeo
    Nezu, Yasuko
    Akiyama, Shoko
    Cole, Ashley L.
    Yang, Shibing
    Mu, George
    Katsumata, Masayuki
    Komatsubara, Masaki
    Alfonso-Cristancho, Rafael
    PULMONARY PHARMACOLOGY & THERAPEUTICS, 2022, 75
  • [43] Real-World Healthcare Resource Utilization (HRU) and Costs of Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Receiving Eculizumab in a US Population
    Cheng, Wendy Y.
    Sarda, Sujata P.
    Mody-Patel, Nikita
    Krishnan, Sangeeta
    Yenikomshian, Mihran
    Mahendran, Malena
    Lejeune, Dominique
    Yu, Louise H.
    Duh, Mei Sheng
    ADVANCES IN THERAPY, 2021, 38 (08) : 4461 - 4479
  • [44] Incidence of acute exacerbation of idiopathic pulmonary fibrosis in patients receiving antifibrotic agents: Real-world experience
    Isshiki, Takuma
    Sakamoto, Susumu
    Yamasaki, Akira
    Shimizu, Hiroshige
    Miyoshi, Shion
    Nakamura, Yasuhiko
    Homma, Sakae
    Kishi, Kazuma
    RESPIRATORY MEDICINE, 2021, 187
  • [45] Economic burden of alopecia areata: A study of direct and indirect cost in Japan using real-world data
    Ohyama, Manabu
    Kamei, Kazumasa
    Yuasa, Akira
    Anderson, Peter
    Milligan, Gary
    Sakaki-Yumoto, Masayo
    JOURNAL OF DERMATOLOGY, 2023, 50 (10) : 1246 - 1254
  • [46] Real-World Treatment Outcomes, Healthcare Resource Use, and Costs Associated with Antiemetics Among Cancer Patients on Cisplatin-Based Chemotherapy
    Navari, Rudolph M.
    Nelson, Winnie W.
    Shoaib, Sofia
    Singh, Risho
    Zhang, Weiping
    Bailey, William L.
    ADVANCES IN THERAPY, 2023, 40 (07) : 3217 - 3226
  • [47] Dose Escalation and Healthcare Resource Use among Ulcerative Colitis Patients Treated with Adalimumab in English Hospitals: An Analysis of Real-World Data
    Black, Christopher M.
    Yu, Eric
    McCann, Eilish
    Kachroo, Sumesh
    PLOS ONE, 2016, 11 (02):
  • [48] Real-World Healthcare Resource Use Associated with Recurrent or Metastatic Head and Neck Cancer Patients Care in Portugal-TRACE Study
    Teixeira, Maria Margarida
    Dias, Joao
    Andre, Teresa
    Joaquim, Ana
    Fernandes, Ricardo
    Magalhaes, Joana
    Marreiros, Laura
    Pinto, Leonor
    Ribeiro, Leonor
    Nogueira, Mafalda
    Morais, Catarina
    CURRENT ONCOLOGY, 2024, 31 (08) : 4270 - 4283
  • [49] Dupilumab responder types and predicting factors in patients with type 2 severe asthma: A real-world cohort study
    Bult, L.
    Thelen, J. C.
    Rauh, S. P.
    in't Veen, J. C. C. M.
    Braunstahl, G. J.
    RESPIRATORY MEDICINE, 2024, 231
  • [50] Real-World Evidence on the Diagnostic and Clinical Characteristics of Asthma in Japanese Patients with COPD: The ACO Japan Cohort Study
    Hashimoto, Shu
    Yoshida, Yuri
    Makita, Naoyuki
    Sorimachi, Ryoko
    Sugaya, Satoko
    Arita, Yoshifumi
    Hayashi, Nobuya
    Tashiro, Naoki
    Ichinose, Masakazu
    INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE, 2023, 18 : 37 - 46